Takeshi Namekawa
Overview
Explore the profile of Takeshi Namekawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
329
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nouruzi S, Namekawa T, Tabrizian N, Kobelev M, Sivak O, Scurll J, et al.
JCI Insight
. 2024 Oct;
9(23).
PMID: 39470735
Lineage plasticity mediates resistance to androgen receptor pathway inhibitors (ARPIs) and progression from adenocarcinoma to neuroendocrine prostate cancer (NEPC), a highly aggressive and poorly understood subtype. Neuronal transcription factor ASCL1...
2.
Tabrizian N, Nouruzi S, Cui C, Kobelev M, Namekawa T, Lodhia I, et al.
Cell Rep
. 2023 Aug;
42(8):112937.
PMID: 37552603
Lineage plasticity is a form of therapy-induced drug resistance. In prostate cancer, androgen receptor (AR) pathway inhibitors potentially lead to the accretion of tumor relapse with loss of AR signaling...
3.
Nouruzi S, Ganguli D, Tabrizian N, Kobelev M, Sivak O, Namekawa T, et al.
Nat Commun
. 2022 Apr;
13(1):2282.
PMID: 35477723
Treatment with androgen receptor pathway inhibitors (ARPIs) in prostate cancer leads to the emergence of resistant tumors characterized by lineage plasticity and differentiation toward neuroendocrine lineage. Here, we find that...
4.
Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, et al.
Nat Cell Biol
. 2021 Sep;
23(9):1023-1034.
PMID: 34489572
Cancers adapt to increasingly potent targeted therapies by reprogramming their phenotype. Here we investigated such a phenomenon in prostate cancer, in which tumours can escape epithelial lineage confinement and transition...
5.
Kamada S, Namekawa T, Ikeda K, Suzuki T, Kagawa M, Takeshita H, et al.
Oncogene
. 2021 May;
40(22):3899-3913.
PMID: 33972682
Tyrosine kinase inhibitors (TKIs) are used as targeted drugs for advanced renal cell carcinoma (RCC), although most cases eventually progress by acquiring resistance. Cancer stemness plays critical roles in tumor...
6.
Namekawa T, Kitayama S, Ikeda K, Horie-Inoue K, Suzuki T, Okamoto K, et al.
Cancer Lett
. 2020 Jun;
489:79-86.
PMID: 32544513
Testicular germ cell tumor (GCT) is the most common type of malignancy in young males. Patients with nonseminomatous GCT still have poor prognosis. To identify new therapeutic targets, we generated...
7.
Namekawa T, Ikeda K, Horie-Inoue K, Suzuki T, Okamoto K, Ichikawa T, et al.
Int J Cancer
. 2019 Jun;
146(4):1099-1113.
PMID: 31187490
Acquired chemoresistance is a critical issue for advanced bladder cancer patients during long-term treatment. Recent studies reveal that a fraction of tumor cells with enhanced tumor-initiating potential, or cancer stem-like...
8.
Namekawa T, Ikeda K, Horie-Inoue K, Inoue S
Cells
. 2019 Jan;
8(1).
PMID: 30669516
Various preclinical models have been developed to clarify the pathophysiology of prostate cancer (PCa). Traditional PCa cell lines from clinical metastatic lesions, as exemplified by DU-145, PC-3, and LNCaP cells,...
9.
Namekawa T, Imamoto T, Kato M, Komiya A, Ichikawa T
Reprod Med Biol
. 2018 Nov;
17(4):343-355.
PMID: 30377390
Background: In the era of improving assisted reproductive technology (ART), patients with obstructive azoospermia (OA) have 2 options: vasal repair or testicular sperm extraction with intracytoplasmic sperm injection. Vasal repair,...
10.